154 related articles for article (PubMed ID: 24803183)
21. The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration.
Fraga A; Ribeiro R; Príncipe P; Lobato C; Pina F; Maurício J; Monteiro C; Sousa H; Calais da Silva F; Lopes C; Medeiros R
Eur J Cancer; 2014 Jan; 50(2):359-65. PubMed ID: 24090974
[TBL] [Abstract][Full Text] [Related]
22. Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women.
Straume AH; Knappskog S; Lønning PE
J Steroid Biochem Mol Biol; 2012 Jan; 128(1-2):69-75. PubMed ID: 21939764
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
24. Single nucleotide polymorphisms in DKK3 gene are associated with prostate cancer risk and progression.
Kim MS; Lee HN; Kim HJ; Myung SC
Int Braz J Urol; 2015; 41(5):869-97. PubMed ID: 26689513
[TBL] [Abstract][Full Text] [Related]
25. CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium.
Travis RC; Schumacher F; Hirschhorn JN; Kraft P; Allen NE; Albanes D; Berglund G; Berndt SI; Boeing H; Bueno-de-Mesquita HB; Calle EE; Chanock S; Dunning AM; Hayes R; Feigelson HS; Gaziano JM; Giovannucci E; Haiman CA; Henderson BE; Kaaks R; Kolonel LN; Ma J; Rodriguez L; Riboli E; Stampfer M; Stram DO; Thun MJ; Tjønneland A; Trichopoulos D; Vineis P; Virtamo J; Le Marchand L; Hunter DJ
Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2734-44. PubMed ID: 19789370
[TBL] [Abstract][Full Text] [Related]
26. Association of endothelin-1 gene single-nucleotide polymorphisms and haplotypes with risk of hormone refractory prostate cancer.
Xu D; Wang X; Lou Y
Pharmazie; 2017 Feb; 72(2):103-106. PubMed ID: 29441862
[TBL] [Abstract][Full Text] [Related]
27. Genetic variation in the COX-2 gene and the association with prostate cancer risk.
Shahedi K; Lindström S; Zheng SL; Wiklund F; Adolfsson J; Sun J; Augustsson-Bälter K; Chang BL; Adami HO; Liu W; Grönberg H; Xu J
Int J Cancer; 2006 Aug; 119(3):668-72. PubMed ID: 16506214
[TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphism in sex hormone metabolism and prostate cancer risk.
Ersekerci E; Sofikerim M; Taheri S; Demirtas A; Halis F
Genet Mol Res; 2015 Jul; 14(3):7326-34. PubMed ID: 26214411
[TBL] [Abstract][Full Text] [Related]
29. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
[TBL] [Abstract][Full Text] [Related]
30. Haplotype analyses of CYP19A1 gene variants and breast cancer risk: results from the Shanghai Breast Cancer Study.
Cai Q; Kataoka N; Li C; Wen W; Smith JR; Gao YT; Shu XO; Zheng W
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):27-32. PubMed ID: 18199708
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy.
Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025
[TBL] [Abstract][Full Text] [Related]
32. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
33. Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients.
Lin VC; Huang CY; Lee YC; Yu CC; Chang TY; Lu TL; Huang SP; Bao BY
Arch Toxicol; 2014 Apr; 88(4):901-11. PubMed ID: 24448834
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.
Ferraldeschi R; Arnedos M; Hadfield KD; A'Hern R; Drury S; Wardley A; Howell A; Evans DG; Roberts SA; Smith I; Newman WG; Dowsett M
Breast Cancer Res Treat; 2012 Jun; 133(3):1191-8. PubMed ID: 22418701
[TBL] [Abstract][Full Text] [Related]
35. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
36. Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer.
Miron L; Negură L; Peptanariu D; Marinca M
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):997-1004. PubMed ID: 23700878
[TBL] [Abstract][Full Text] [Related]
37. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk.
Sun J; Wiklund F; Zheng SL; Chang B; Bälter K; Li L; Johansson JE; Li G; Adami HO; Liu W; Tolin A; Turner AR; Meyers DA; Isaacs WB; Xu J; Grönberg H
J Natl Cancer Inst; 2005 Apr; 97(7):525-32. PubMed ID: 15812078
[TBL] [Abstract][Full Text] [Related]
38. Estrogen receptor beta polymorphism is associated with prostate cancer risk.
Thellenberg-Karlsson C; Lindström S; Malmer B; Wiklund F; Augustsson-Bälter K; Adami HO; Stattin P; Nilsson M; Dahlman-Wright K; Gustafsson JA; Grönberg H
Clin Cancer Res; 2006 Mar; 12(6):1936-41. PubMed ID: 16551880
[TBL] [Abstract][Full Text] [Related]
39. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
Hussain M; Tangen CM; Higano C; Schelhammer PF; Faulkner J; Crawford ED; Wilding G; Akdas A; Small EJ; Donnelly B; MacVicar G; Raghavan D;
J Clin Oncol; 2006 Aug; 24(24):3984-90. PubMed ID: 16921051
[TBL] [Abstract][Full Text] [Related]
40. Survival and clinical metastases among prostate cancer patients treated with androgen deprivation therapy in Sweden.
Banefelt J; Liede A; Mesterton J; Stålhammar J; Hernandez RK; Sobocki P; Persson BE
Cancer Epidemiol; 2014 Aug; 38(4):442-7. PubMed ID: 24875326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
